Objectives: Idiopathic pulmonary fibrosis (IPF) is a rare, fatal lung disease. Pirfenidone is a
novel treatment for IPF patients. This analysis sought to predict survival with pirfenidone …

Background: Although phase 3 trials showed significant efficacy and acceptable safety
profiles for pirfenidone in mild-to-moderate idiopathic pulmonary fibrosis (IPF), data on …

Introduction In this study we aimed to investigate the effectiveness and safety profile of
pirfenidone for the treatment of idiopathic pulmonary fibrosis (IPF) in a real-life setting …

Patients with idiopathic pulmonary fibrosis, an incurable, progressive fibrotic interstitial lung
disease, suffer an impaired quality of life due to symptoms, resultant functional limitations …

Background Two antifibrotic drugs, pirfenidone and nintedanib, are approved by the
European Medicines Agency and the US Food and Drug Administration for the treatment of …

Background: Clinical practice guidelines for the treatment of idiopathic pulmonary fibrosis
(IPF) currently recommend pirfenidone and nintedanib. However, there is a lack of evidence …

Idiopathic pulmonary fibrosis (IPF) is a progressive disease leading to significant morbidity
and mortality. In 2017 the Thoracic Society of Australia and New Zealand (TSANZ) and Lung …

Idiopathic pulmonary fibrosis (IPF) is a progressively fibrotic disease, with no effective
treatment and a median survival time of 2–5 yrs. The search for effective treatment has …

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a chronic progressive age-related
lung disease causing relentless fibrosis of the lung parenchyma. Currently, pirfenidone and …

Methods: Using the rate of decline in FVC% predicted in the 12 months prior to pirfenidone,
patients were stratified into slow (< 5%) or rapid (≥ 5%) decliner groups. Comparisons in …